The lecture will cover the currently approved indications for use of Lipiodol® (Ethiodized Oil) Injection as an imaging biomarker for the therapy of liver cancer, discuss biological and physiological properties of Lipiodol, offer clinical and preclinical evidence for outcomes of liver-directed therapies with Lipiodol and provide an overview of applications for the use of Lipiodol as a marker for tumor necrosis and treatment response across multiple imaging modalities, including intra-procedural imaging.
Julius Chapiro, MD
Co-Director, Interventional Oncology Research Lab
Yale School of Medicine
Dr. Chapiro's research focuses on developing new quantitative imaging biomarkers for the diagnosis, characterization, and therapeutic management of liver cancer. His current interest and ongoing research focus on developing? new tools to characterize the tumor microenvironment in the setting of loco-regional, image-guided therapies of? liver cancer. Creating innovative and clinically applicable imaging solutions for liver cancer with advanced? molecular imaging, image post-processing and machine learning approaches and translating them to clinical? practice has been his central mission for the past seven years.
With more than 80 original research articles,? numerous reviews and book chapters and >100 invited lectures, workshops, and advisory board participations? within the last five years, his research has also resulted in several filed patent applications, 510(k)-approved? medical products and significant grant support from federal (NIH-NCI), foundational (e.g. Society of? Interventional Oncology, Radiological Society of North America, German-Israeli Foundation, Rolf W. Guenther? Foundation) and industry sources (Boston Scientific, Philips and Guerbet).
He is an active research mentor to? >30 undergraduate, medical and PhD-level graduate students and peers, and work closely with several senior? mentors in interventional oncology and biomedical science both at Yale and other national and international? institutions. Being an active contributor, program coordinator, journal, abstract- and grant reviewer in several? professional societies (RSNA, SIR and WCIO/SIO), he is also committed to education and the mission of? disseminating research data and scientific knowledge. He has a track record of organizing and leading multidisciplinary? research teams in several academic institutions, including Johns Hopkins University, Charite Berlin, and Yale? University. He is committed to scientifically leading and? implementing his vision of translating ground-breaking research into clinical application to improve patient? care.
Lipiodol Important Safety Information
Indications and Usage
LIPIODOL® (ethiodizedoil) injection is a prescription oil-based radio-opaque contrast agent indicated for:
LIPIODOL® is contraindicated in patients with hypersensitivity to LIPIODOL®, hyperthyroidism, traumatic injuries, recent hemorrhage or bleeding.
Warnings and Precautions
Use in Specific Populations
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
1. Lipiodol Prescribing Information. Princeton, NJ: Guerbet, LLC, 2018.